Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

Author： Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.7, 2011-07, pp. : 1375-1383

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

By Farlow Martin R.   Alva Gus   Meng Xiangyi   Olin Jason T.  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 263-269

Informa Healthcare

Access to resources Recommend Favorite

Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

By Gauthier Serge  

Current Medical Research and Opinion, Vol. 29, Iss. 8, 2013-08 ,pp. : 989-1000

Informa Healthcare

Access to resources Recommend Favorite

Health-Related Quality-of-Life Outcomes in Patients Treated with Push-Pull OROS Hydromorphone versus Extended-Release Oxycodone for Chronic Hip or Knee Osteoarthritis Pain: A Randomized, Open-Label, Parallel-Group, Multicenter Study

By Gajria Kavita  

The Patient: Patient-Centered Outcomes Research, Vol. 1, Iss. 3, 2008-01 ,pp. : 223-238

Adis International

Access to resources Recommend Favorite

Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan (MILAI study)

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 612-622

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

By Aupperle Peter M.   Koumaras Barbara   Chen Michael   Rabinowicz Adrian   Mirski Dario  

Current Medical Research and Opinion, Vol. 20, Iss. 10, 2004-10 ,pp. : 1605-1612

Informa Healthcare

Access to resources Recommend Favorite